Brokers are bullish on these 4 ASX 200 shares

Big brokers are bullish on ASX 200 shares including Brickworks Limited (ASX: BKW) and Polynovo Ltd (ASX: PNV)

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Big brokers have run the ruler on new announcements and notable share price movements. Here are the ASX 200 shares that have been upgraded to a buy or buy equivalent rating on Thursday. 

4 bullish ASX 200 shares 

Bapcor Ltd (ASX: BAP

Bapcor announced its plans to expand into Asia by acquiring 25% of the issued equity of Tye Soon. Tye Soon is an independent automotive parts distributor in South East and North East Asia, distributing a wide range of parts and aftermarket parts. Bapcor will invest approximately SGD$12.5 million for the 25% stake and work together to maximise opportunities in the Asia and Australasia region. 

Citi believes the acquisition will provide Bapcor with a base to grow its Asian business and address the gaps in its specialist wholesale portfolio. The broker eyes South Korea and Malaysia (43% of Tye Soon's revenue) as key rollout opportunities for Bapcor in Asia. 

Citi retained a buy rating with a $9.35 target price, representing an upside of approximately 26%.

Brickworks Limited (ASX: BKW

The Brickworks share price is on the rise today after announcing its half-year results. At the time of writing, Brickworks shares were trading for $19.80, up 4.7%.

The building products company reported a 4% decline in revenue to $432 million. Earnings before interest and tax (EBIT) fell 6% to $127 million. 

These results were better than expected from Citi's point of view and were boosted by revaluations and sales of property. Excluding property, the operational performance came in below expectations, driven by a weaker Australian building products segment. 

The broker retained a buy rating with the belief that its outlook is improving. Its target price of $22.70 represents an upside of approximately 20% at today's prices. 

Graincorp Ltd (ASX: GNC

Graincorp upgraded its earnings on Wednesday on the back of new operating initiative and completion of its international expansion. This is expected to increase its 'through-the-cycle' earnings which refers to a notional year of average East Coast Australia grain production and average tonnes handled by GrainCorp.

Credit Suisse believes the market has underrated the cost reductions that Graincorp has made over the years. The broker also increased its medium-term forecasts, in-line with the company's new earnings before taxes, depreciation, and amortisation EBITDA guidance. 

The broker upgraded Graincorp shares to outperform with a $5.59 target price. With the Graincorp share price pushing another 2.6% higher today to $5.13, the target price represents an upside just shy of 10%. 

Polynovo Ltd (ASX: PNV

The Polynovo share price is making a strong recovery this month after losing more than 30% in value between late December 2020 and mid January 2021. 

The company missed earnings expectations when it updated the market back in January. The update reported a 31% increase in sales vs. the commentary from Polynovo managing director that revenue would double again in FY21. 

Macquarie Group Ltd (ASX: MQG) believe Polynovo could get back on track with its entry into sizeable markets such as chronic wounds and hernia to support growth in the medium to long term. 

The broker upgraded Polynovo shares from neutral to outperform with a $3.20 target price. The Polynovo share price has surged more than 20% this month to $3.02 at the time of writing. The target price represents an upside of 5.40%. 

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia owns shares of and has recommended Bapcor and Brickworks. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were nervous this Friday, ending the week on a sour note.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Where to invest $5,000 into ASX 200 shares this month

The team at Bell Potter is bullish on these names. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
52-Week Highs

8 ASX 200 shares hitting multi-year highs today

These shares have defied the trend, hitting new price milestones amid a day in the red for the ASX 200.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why EOS, Evolution Mining, Renascor, and Woodside shares are jumping today

These shares are ending the week on a high. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Accent, Cettire, Ioneer, and Pro Medicus shares are dropping today

These shares are ending the week in the red. What's going on?

Read more »

A group of three miners in hard hats and high visibility vests confer at a rocky mining site.
Broker Notes

Up 66% in a year, just how much more upside does Macquarie tip for Perseus Mining shares?

Just how much higher might Perseus Mining shares soar? Here’s what Macquarie had to say about the ASX 200 gold…

Read more »

Rising share price chart.
Broker Notes

Why this exciting ASX 200 share could rise almost 50%

Bell Potter has good things to say about this biopharmaceutical company.

Read more »